Strides Pharma Science Ltd
STARStrides Pharma Science Ltd
STARPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
1,928.64 | 6.22 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 6.64 | 0.47% |
Forecast & Ratings
Detailed Forecast from 4 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,961.59 | 3,097.80 | 3,534.85 | 2,545.66 | 2,909.44 | 3,518.84 | 3,259.23 | 3,935.35 | 4,145.60 | 4,306.63 | ||||||||||
Raw Materials | 1,612.38 | 1,432.25 | 1,286.65 | 1,189.20 | 1,167.29 | 1,686.50 | 1,407.04 | 1,629.55 | 1,624.56 | 3,756.40 | ||||||||||
Power & Fuel Cost | 77.18 | 33.87 | 51.33 | 54.39 | 64.49 | 64.58 | 71.54 | 85.82 | 86.48 | |||||||||||
Employee Cost | 357.70 | 419.16 | 434.05 | 329.44 | 442.56 | 550.15 | 646.91 | 732.02 | 751.13 | |||||||||||
Selling & Administrative Expenses | 323.35 | 339.47 | 409.34 | 276.20 | 338.51 | 473.78 | 577.98 | 526.31 | 477.75 | |||||||||||
Operating & Other expenses | 154.11 | 54.45 | 313.14 | 196.74 | 525.25 | 98.10 | 798.52 | 724.88 | 733.28 | |||||||||||
EBITDA | 436.87 | 818.60 | 1,040.34 | 499.69 | 371.34 | 645.73 | -242.76 | 236.77 | 472.40 | 550.23 | ||||||||||
Depreciation/Amortization | 131.25 | 126.15 | 154.04 | 117.39 | 173.70 | 206.29 | 233.01 | 243.25 | 220.68 | 209.69 | ||||||||||
PBIT | 305.62 | 692.45 | 886.30 | 382.30 | 197.64 | 439.44 | -475.77 | -6.48 | 251.72 | 340.54 | ||||||||||
Interest & Other Items | 168.17 | 183.10 | 196.24 | 79.29 | 155.72 | 150.07 | 176.74 | 261.14 | 314.45 | 318.42 | ||||||||||
PBT | 137.45 | 509.35 | 690.06 | 303.01 | 41.92 | 289.37 | -652.51 | -267.62 | -62.73 | 22.12 | ||||||||||
Taxes & Other Items | 28.92 | 109.60 | 25.55 | -21.60 | 5.53 | 20.94 | -192.30 | -65.00 | 7.89 | 15.44 | ||||||||||
Net Income | 108.53 | 399.75 | 664.51 | 324.61 | 36.39 | 268.43 | -460.21 | -202.62 | -70.62 | 6.68 | ||||||||||
EPS | 14.10 | 43.28 | 71.89 | 35.67 | 4.06 | 29.95 | -51.29 | -22.50 | -7.75 | 0.73 | ||||||||||
DPS | 4.84 | 4.36 | 1.94 | 3.00 | 14.00 | 2.50 | 0.00 | 1.50 | — | 1.50 | ||||||||||
Payout ratio | 0.34 | 0.10 | 0.03 | 0.08 | 3.45 | 0.08 | 0.00 | — | 0.00 | 2.06 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Strides Pharma Science Ltd | -182.43 | 6.22 | — |
Sun Pharmaceutical Industries Ltd | 48.19 | 6.88 | 0.70% |
Cipla Ltd | 32.68 | 5.02 | 0.78% |
Torrent Pharmaceuticals Ltd | 68.98 | 16.66 | 0.83% |
Price Comparison
Compare STAR with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 1.54%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.14%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Strides Pharma Science Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.4750% | Percentage of the fund’s portfolio invested in the stock 1.75% | Change in the portfolio weight of the stock over the last 3 months 0.58% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/109 (0) |
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9628% | Percentage of the fund’s portfolio invested in the stock 1.09% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 21/84 (+5) |
Quant Active Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4791% | Percentage of the fund’s portfolio invested in the stock 1.69% | Change in the portfolio weight of the stock over the last 3 months 0.44% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/72 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2024
Dividend/Share
₹2.50
Ex DateEx Date
Sep 9, 2024
Cash Dividend
Ex DateEx DateAug 4, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Aug 4, 2023
Cash Dividend
Ex DateEx DateAug 5, 2021
Dividend/Share
₹2.50
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateJul 24, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Jul 24, 2020
Cash Dividend
Ex DateEx DateAug 22, 2019
Dividend/Share
₹12.00
Ex DateEx Date
Aug 22, 2019
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine Tablets of TWi Pharmaceuticals, Inc. Fluoxetine is an antidepressant of the Selective Serotonin Reuptake Inhibitor (SSRI) class. It is used for the treatment of Major Depressive Disorder (MDD), Obsessive'Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, with or without Agoraphobia. With the approval of the Fluoxetine Tablets, the company is now positioned to offer a complete portfolio of Fluoxetine across capsules and tablets in 10 mg, 20 mg and 60 mg strengths. Fluoxetine capsules and tablets have a combined market size of around $130 millions as per (Intercontinental Marketing Services Health Inc) IMS. The addition of the Fluoxetine Tablets will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company's facility in Puducherry. Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche Pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. The counter hit an all-time high of Rs 1,430.80 in intraday today.Powered by Capital Market - Live
Strides Pharma Science announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Fluoxetine Tabs 60 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine Tablets, 60 mg, of TWi Pharmaceuticals, Inc. With the approval of the Fluoxetine Tabs 60 mg strength, the Company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths. Fluoxetine Capsules and Tablets have a combined market size of ~US$ 130 Mn as per IMS. The addition of the Fluoxetine Tabs 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The Company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company's facility in Puducherry.Powered by Capital Market - Live
Strides Pharma Science (Strides) today announced that it has secured the approval of its equity shareholders and secured creditors with overwhelming majority , along with those of OneSource Specialty Pharma and SteriScience Specialties, in meetings convened under the guidance of the Hon'ble National Company Law Tribunal (NCLT). All the secured creditors who voted on the Scheme for the three Companies in their respective meetings, were in favour of the Scheme. This is a critical step in the creation of OneSource and the support from Shareholders and Secured Creditors underscores the confidence in the Company's strategic initiative to create OneSource - India's first specialty pharma Contract Development and Manufacturing Organization (CDMO) covering advanced sectors like biologics, complex injectables, and oral technologies, including soft-gelatin capsules. In September 2023, Strides announced its strategic initiative to create OneSource as an Independent Specialty Pharma CDMO by integrating the Oral Technologies (Soft Gelatin Capsules) business from Strides, Sterile Injectables business of SteriScience Specialty and the Biologics and high-end drug devices combination business of OneSource (erstwhile Stelis). Having already received Stock Exchange approvals in May 2024, this latest approval from Equity Shareholders and Secured Creditors marks a significant milestone. The Company will now seek final approval from the Hon'ble NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE.Powered by Capital Market - Live
Strides Pharma Science announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Strides Pharma Science (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. , Singapore, has received approval for the generic version of Theophylline Extended-Release Tablets, 300 mg and 450 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), THEO-DUR', of Schering Corp. Theophylline extended-release tablets are indicated for the treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of ~US$ 11.5 mn, with the 300 mg dosage contributing ~US$ 10.8 mn as per IQVIA. The Theophylline Extended-Release Tablets, 300 mg and 450 mg will be manufactured at the company's flagship facility in KRS Gardens in Bangalore, India.Powered by Capital Market - Live
Strides Pharma Science has fixed 09 September 2024 as record date for final dividend of Rs 2.50 per share. Powered by Capital Market - Live
The good manufacturing practices (GMP) inspection was conducted from 1 April to 5 April 2024. The USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Strides Alathur facility caters to the U.S. and other regulated markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets. Strides remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets, the company stated in exchange filing. Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. The scrip declined 1.27% to Rs 1,297 on the BSE. Powered by Capital Market - Live
Strides Alathur, a wholly owned subsidiary of Strides Pharma Science (Strides) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility at Alathur, Chennai thereby successfully concluding the Good Manufacturing Practices (GMP) inspection conducted between April 1-5, 2024. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). Strides Alathur facility caters to the U.S. and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.Powered by Capital Market - Live
Strides Pharma, as a part of Group entites optimization exercises has liquidated its US unit by the relevant regulatory authorities of New Jersey. Altima Innovations Inc. was a non-operative entity so, its turnover for FY 2024 was NIL. The net worth of the company for FY ended 31 March 2024 was $6,620 (equivalent to approximately Rs 551,909). Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. The company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24. Revenue from operations stood at Rs 1,087.50 crore in the quarter ended June 2024, registering a growth of 16.93% YoY. Shares of Strides Pharma Science hit 52-week high of Rs 1,298.50 in today's intraday session. Powered by Capital Market - Live
Strides Pharma Science announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 September 2024 .Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.24%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.16% to 1.1%